Patients with coronary artery disease who have obstructive sleep apnea may benefit from adding CPAP intervention to their lipid-lowering medication, according to the RICCADSA trial.
Dyslipidaemia is a well-known risk factor for coronary artery disease (CAD), and managing these high-risk people requires lowering lipid levels as a secondary preventative measure. Additionally, patients with obstructive sleep apnea frequently have dyslipidaemia (OSA). The initial course of treatment for OSA is continuous positive airway pressure (CPAP). Evidence of CPAP's potential lipid-lowering benefits in CAD patients with OSA is, however, lacking...